# Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

> **NCT01841021** · NA · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT01841021
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual, loss of sponsor support
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01841021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01841021, "Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01841021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*